Research Analysts Offer Predictions for Day One Biopharmaceuticals, Inc.’s Q2 2023 Earnings (NASDAQ:DAWN)

Posted by Defense World Staff on May 5th, 2023

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) – Equities research analysts at Capital One Financial decreased their Q2 2023 EPS estimates for Day One Biopharmaceuticals in a research note issued on Tuesday, May 2nd. Capital One Financial analyst N. Quibria now anticipates that the company will earn ($0.64) per share for the quarter, down from their prior forecast of ($0.60). Capital One Financial has a “Overweight” rating and a $40.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.49) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals’ Q3 2023 earnings at ($0.66) EPS, Q4 2023 earnings at ($0.68) EPS, FY2023 earnings at ($2.57) EPS, Q1 2024 earnings at ($0.54) EPS, Q2 2024 earnings at ($0.56) EPS, Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.63) EPS, FY2024 earnings at ($2.32) EPS, FY2025 earnings at ($1.69) EPS and FY2026 earnings at ($0.57) EPS.

Several other brokerages have also recently issued reports on DAWN. Needham & Company LLC dropped their price objective on shares of Day One Biopharmaceuticals from $48.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, April 5th. Bank of America downgraded shares of Day One Biopharmaceuticals from a “buy” rating to an “underperform” rating in a research report on Tuesday, April 25th. Piper Sandler increased their target price on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Sunday, January 8th. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Day One Biopharmaceuticals in a report on Tuesday, March 7th. Finally, Oppenheimer initiated coverage on Day One Biopharmaceuticals in a research report on Thursday, February 2nd. They set a “market perform” rating for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and an average target price of $43.57.

Day One Biopharmaceuticals Price Performance

Shares of Day One Biopharmaceuticals stock opened at $13.58 on Thursday. The stock has a market capitalization of $999.12 million, a price-to-earnings ratio of -6.26 and a beta of -2.07. The firm’s fifty day simple moving average is $15.17 and its 200-day simple moving average is $18.87. Day One Biopharmaceuticals has a 12 month low of $5.44 and a 12 month high of $28.35.

Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last released its quarterly earnings data on Monday, May 1st. The company reported ($0.59) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.59).

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $18.05, for a total value of $180,500.00. Following the completion of the transaction, the insider now directly owns 1,233,660 shares of the company’s stock, valued at $22,267,563. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 7th. The stock was sold at an average price of $20.01, for a total transaction of $250,125.00. Following the completion of the sale, the chief executive officer now directly owns 1,174,276 shares of the company’s stock, valued at approximately $23,497,262.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $18.05, for a total value of $180,500.00. Following the completion of the transaction, the insider now directly owns 1,233,660 shares of the company’s stock, valued at $22,267,563. The disclosure for this sale can be found here. Insiders sold a total of 37,126 shares of company stock worth $721,856 over the last 90 days. 8.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. grew its position in Day One Biopharmaceuticals by 5,969.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,894,537 shares of the company’s stock worth $33,912,000 after purchasing an additional 1,863,325 shares during the period. State Street Corp grew its stake in Day One Biopharmaceuticals by 469.1% in the 3rd quarter. State Street Corp now owns 2,041,738 shares of the company’s stock worth $40,896,000 after acquiring an additional 1,682,955 shares in the last quarter. Braidwell LP bought a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $26,826,000. Pathway Capital Management LP lifted its position in Day One Biopharmaceuticals by 147.0% during the fourth quarter. Pathway Capital Management LP now owns 995,686 shares of the company’s stock valued at $21,427,000 after acquiring an additional 592,559 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Day One Biopharmaceuticals by 29.5% in the third quarter. BlackRock Inc. now owns 2,541,235 shares of the company’s stock worth $50,901,000 after buying an additional 578,511 shares during the last quarter. Hedge funds and other institutional investors own 86.08% of the company’s stock.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.